IFN Assay Type I Ready Cells

$950.00

The iLite Type I IFN Assay Ready Cells can be used for measuring the bioactivity of Type I Interferon or neutralizing antibodies to Interferon beta or Neutralizing antibodies to Interferon alpha. The Eagle Biosciences iLite Type I IFN Assay Ready Cells are for research use only.

SKU: BM3049 Categories: ,

iLite Type I IFN Assay Ready Cells

IFN Assay Ready Cells Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite Type IIFN Assay Ready Cells are intended for:

  • Quantification of interferon alpha or beta activity
  • Determination of Interferon alpha or beta NAbs

Content: iLite® Type I IFN Assay Ready Cells 1 vial (2.5mL)
Alternative Names: Type I Interferon Assay Ready Cells
For Research Use Only


Key benefits of iLite® Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (>10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Overview

In this product, human cells (U937, ATCC# CRL1593.2) engineered to express Firefly Luciferase under the control of an IFN α/β responsive promoter. When IFNα or IFNβ binds to the IFN α/β receptor on the cell surface, the IFN α/β regulated Firefly Luciferase reporter gene construct will be activated, resulting in a luminescent signal.


Principle

Interferon alpha (IFNα) has been widely used to treat chronic viral hepatitis and a wide variety of malignant diseases, including hairy cell leukemia, basal cell carcinoma, chronic myeloid leukemia and cutaneous T-cell lymphoma. Several different recombinant preparations of IFNα are available commercially; the most commonly used formulations include IFNα2a and IFNα2b. A number of studies have shown that development of anti-IFNα neutralizing antibodies (NAbs) is correlated with a loss of IFNα treatment efficacy. Interferon beta (IFNβ) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAbs and binding antibodies (BAbs) to IFNβ has been widely reported. Subjects with NAbs have shown reduced response to treatment with IFNβ, having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAbs vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.


Products Related to IFN Assay Ready Cells

iLite Insulin Assay Ready Cells
iLite FGF-21 Assay Ready Cells
iLite IL-2 Assay Ready Cells

Additional Information

Principle


iLite® Type I IFN Assay Ready Cells are growth arrested cells which are sensitive to human Type I Interferon. The cells can be used in a number of different assays for measuring the bioactivity of Type I Interferon or NAb’s to IFN beta or NAb’s to IFN alpha.

Type I Interferons are produced by a wide variety of cells in response to viral infection and hence the presence of type I interferon is indicative of infection. IFN alpha is routinely used to treat chronic viral hepatitis and a wide variety of malignant diseases and IFN beta is routinely used to treat multiple sclerosis. The development of neutralizing antibodies (NAb’s) to either IFN alpha or IFN beta which correlates with a loss of treatment efficacy, is relatively common 1-2. The iLite® IFN cells are the only commercially available cells capable of measuring either the bioactivity of type I interferon, NAb’s to IFN beta or NAb’s to IFN alpha.

Manual

Product Manual


Frequently Asked Questions


Publications

References


1. Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A, on behalf of the ABIRISK consortium: Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. J Immunol Methods 2016; 430: 1-9.